BIOS Fund I, LP's Form 4 filing
Lantern Pharma Inc. (LTRN) · filed Feb 29, 2024
- Accession no.
- 0001104659-24-029534
- Filed
- Feb 29, 2024, 9:54 PM ET
- Trade date
- Feb 27-29, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $676.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BIOS Fund I, LPCIK 0001697316 | 10% Owner |
| BIOS Fund I QP, LPCIK 0001700297 | 10% Owner |
| BIOS Fund II, LPCIK 0001714576 | 10% Owner |
| BIOS Fund II QP, LPCIK 0001716869 | 10% Owner |
| BIOS Fund II NT, LPCIK 0001728851 | 10% Owner |
| Fletcher Aaron G.L.CIK 0001789490 | 10% Owner |
| Bios Equity Partners II, LPCIK 0001813313 | 10% Owner |
| Bios Equity Partners, LPCIK 0001813314 | 10% Owner |
| BIOS Advisors GP, LLCCIK 0001813844 | 10% Owner |
| BIOS Capital Management, LPCIK 0001813845 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Common Stock | SSaleDisposed | −4,649 | $4.40 | −$20,455.6 | 68,997 | Indirect | Duplicate filing |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −6,909 | $4.85 | −$33,508.65 | 62,088 | Indirect | Duplicate filing |
| Feb 29, 2024 | Common Stock | SSaleDisposed | −1,832 | $4.87 | −$8,921.84 | 60,256 | Indirect | Duplicate filing |
| Feb 27, 2024 | Common Stock | SSaleDisposed | −34,731 | $4.40 | −$152,816.4 | 515,412 | Indirect | Duplicate filing |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −51,608 | $4.85 | −$250,298.8 | 463,804 | Indirect | Duplicate filing |
| Feb 29, 2024 | Common Stock | SSaleDisposed | −13,686 | $4.87 | −$66,650.82 | 450,118 | Indirect | Duplicate filing |
| Feb 27, 2024 | Common Stock | SSaleDisposed | −10,620 | $4.40 | −$46,728 | 157,797 | Indirect | Duplicate filing |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −15,780 | $4.85 | −$76,533 | 142,017 | Indirect | Duplicate filing |
| Feb 29, 2024 | Common Stock | SSaleDisposed | −4,185 | $4.87 | −$20,380.95 | 137,832 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.